英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
roano查看　roano　在百度字典中的解释百度英翻中〔查看〕
roano查看　roano　在Google字典中的解释Google英翻中〔查看〕
roano查看　roano　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
    Nadofaragene firadenovec- vncg (ADSTILADRIN) is A recommended treatment option: In the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)* and the AUA SUO Guidelines1 By the International Bladder Cancer Group (IBCG) for high-risk NMIBC after BCG failure for those seeking to avoid radical cystectomy 2
  • ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
    ADSTILADRIN® is the first and only FDA-approved gene therapy for treating adult patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
  • Package Insert - ADSTILADRIN
    ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy designed to deliver a copy of a gene encoding a human interferon-alfa 2b (IFNα2b) to the bladder urothelium
  • Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
    Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy used to treat high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer Includes Adstiladrin side effects, interactions and indications
  • FDA Approves Label Update for Nadofaragene Firadenovec in . . .
    The FDA has approved a label update to nadofaragene firadenovec-vncg (Adstiladrin) that introduces an accelerated water bath thawing method completed in approximately 25 minutes, a change intended to streamline clinical preparation for health care teams managing patients with high risk non–muscle-invasive bladder cancer (NMIBC), according to a manufacturer news release 1 Nadofaragene
  • Nadofaragene Firadenovec: First Approval - PubMed
    Abstract Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin ®) is a non-replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) Nadofaragene firadenovec constitutes vector DNA that encodes for interferon (IFN)-α2b and is the
  • Nadofaragene firadenovec-vncg (urinary bladder route)
    Description Nadofaragene Firadenovec-vncg is used to treat patients with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with a tumor type called carcinoma in situ (CIS) with or without papillary tumors This medicine is to be used only by or under the direct supervision of a doctor
  • Nadofaragene Firadenovec-vncg - NCI - National Cancer Institute
    This page contains brief information about nadofaragene firadenovec-vncg and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials
  • Nadofaragene firadenovec - Wikipedia
    Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
  • ADSTILADRIN | FDA
    STN: BLA 125700 Proper Name: nadofaragene firadenovec-vncg Tradename: ADSTILADRIN Manufacturer: Ferring Pharmaceuticals A S Indication: ADSTILADRIN is indicated for the treatment of adult patients





中文字典-英文字典  2005-2009